Poster presentation highlights findings from a study conducted with UT Southwestern Medical Center demonstrating reduction in fungal biofilm and enhanced results when thermal treatment is combined with antifungal therapy. 

Solenic will also host an exhibit booth at the 2026 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting, November 5–8, in Dallas, Texas.

ADDISON, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) — Solenic Medical, a pioneering medical device company focused on developing a non-invasive treatment platform for advanced implant infection care, announced new study findings presented at IDWeek 2026 demonstrating the ability of its thermal technology to reduce fungal biofilm on metallic surfaces. IDWeek is the premier annual joint conference dedicated to infectious diseases, clinical microbiology, healthcare epidemiology, and infection prevention. Conducted in collaboration with UT Southwestern Medical Center, the study extends previous findings demonstrating the technology’s activity against bacterial biofilm and shows that combining AMF with antifungal therapy can further reduce fungal biofilm burden.

Fungal PJI, while less common than bacterial PJI, can be particularly challenging to treat and may result in serious complications. Conventional treatment approaches can involve complex surgical procedures and prolonged antifungal therapies.

Solenic’s proprietary Alternating Magnetic Field (AMF) technology, incorporated into its SOLA-2™ platform, uses a non-invasive thermal mechanism to target biofilm on metallic implants. The platform is designed to generate heat at the implant surface, targeting biofilms through a physical thermal mechanism rather than relying solely on antimicrobial agents. The new study evaluated this mechanism both independently and in combination with antifungal therapies.

“One of the elegant features of our proposed solution to disrupting biofilm on metal implants is that it is thermal in nature,” said Dr. David Greenberg, Professor of Infectious Diseases at UT Southwestern Medical Center and Chief Medical Officer at Solenic Medical. “Given this, we should be able to achieve killing of pathogens regardless of whether they are bacteria or fungi. While we have shown this in bacteria, it remained unclear whether we could achieve similar results in the most common fungal pathogens that are seen in PJI. And in fact, that is what we have demonstrated in this study.”

The findings highlight the potential significance of a technology designed to address both bacterial and fungal biofilms through a single physical mechanism. In laboratory experiments using Candida species grown on stainless steel rings, AMF produced temperature-dependent reductions in viable fungal burden, with multi-log decreases observed as temperatures increased from 60°C to 70°C. In separate experiments involving more established, seven-day biofilms, AMF treatment at 65°C combined with antifungal therapy over three days resulted in greater reductions than either treatment alone. These findings support further investigation of AMF as a potential adjunct to existing antifungal therapies. Further research will be needed to establish the clinical implications of these findings and evaluate the technology’s safety and effectiveness in patients. The full poster presented at IDWeek 2026 is available for review in the Publications section of Solenic Medical’s website at www.solenic.com.

The study reflects the ongoing collaboration between Solenic Medical and UT Southwestern Medical Center to investigate new approaches to one of the most challenging complications in orthopedic care. Solenic continues to advance SOLA-2™ through clinical development, with the goal of providing a non-invasive treatment option for patients with metallic implant-associated infections.

Additionally, Solenic will also participate in the 2026 Annual Meeting of the American Association of Hip and Knee Surgeons (AAHKS), taking place November 5–8 at the Gaylord Texan Resort & Convention Center in the Dallas area. The conference brings together leading orthopedic surgeons, researchers, and industry professionals to discuss advancements in hip and knee replacement surgery. Solenic will host an exhibit at Booth #1625, where attendees can engage with company representatives and learn more about its SOLA-2™ System, ongoing clinical development efforts, and the potential of its non-invasive AMF technology to address metallic implant-associated infections.

In June 2026, Solenic received U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application, authorizing the company to initiate a pivotal clinical trial [AMPLIFY] evaluating its SOLA-2™ System in patients with periprosthetic joint infections.

About Periprosthetic Joint Infections

Prosthetic joint infections occur when microorganisms, most commonly bacteria or fungi, colonize the area around an artificial joint implant. These infections can be difficult to treat because these pathogens may form biofilm on implant surfaces, making them more resistant to antibiotics or antifungals and the host immune response. Current treatment options typically involve surgery including surgical debridement, antibiotics and implant retention (DAIR) in selected patients, or staged revision surgery involving implant removal and replacement.

About Solenic Medical

Solenic Medical is a clinical-stage medical technology company developing non-invasive solutions for metallic implant-associated infections. The Company’s proprietary Alternating Magnetic Field (AMF) platform, SOLA-2TM is designed to address one of the most challenging problems in modern orthopedics: biofilm-related infections. This innovative approach addresses a critical unmet need in orthopedics, crucial for an aging population and increased patient volumes undergoing total joint procedures. Additional metallic implant applications have been identified and protected under patent. For more information, please visit: https://www.solenic.com

SOLA-2™ is an investigational device and has not been approved or cleared by FDA for commercial use.

Forward Looking Statements

This release contains forward-looking statements regarding clinical development, regulatory pathways, commercialization opportunities, and the potential benefits of

SOLA-2. Actual results may differ materially due to risks and uncertainties inherent in clinical development and regulatory review.

Company Contact:

Solenic Medical, Inc.

José F. Guzmán

VP Strategic Marketing

+1 (877) SOLEN1C (765-3612)

jose.guzman@solenic.com

Investor and Media Contact

Daniel Kontoh-Boateng

DKB Partners, LLC

Tel: +1-862-213-1398

dboateng@dkbpartners.net


Primary Logo

Media gallery

About The Author
Solenic Medical, Inc.